DoD Prostate Cancer, Physician Research Award | W81XWH 22 PCRP PRA

Opportunity Information: Apply for W81XWH 22 PCRP PRA

The FY22 DoD Prostate Cancer Research Program (PCRP) Physician Research Award is designed to help early-career physicians build a sustained research career in prostate cancer while they are still managing real clinical responsibilities. The core idea is a mentored, career-building research experience where the physician applicant is the Principal Investigator (PI) and is expected to write the application themselves, with guidance from one or more established mentors. The program places equal weight on two things: the strength and feasibility of the proposed research project, and the quality of the PI's career development plan that shows how the award will move them toward independence in prostate cancer research. Projects may be basic, translational, population science, or clinical research focused, but they must be framed to advance prostate cancer outcomes in ways that matter for Service Members, Veterans, and the broader public.

Eligibility is aimed at physicians at a very specific transition point into independent academic or clinical-investigator work. Applicants must have clinical duties and, by the submission deadline, be either in the final year of an accredited residency or fellowship program, or within five years of starting a faculty appointment (including Instructor roles). A prior track record in prostate cancer research is not required, but the PI must show a clear commitment to becoming a leader at the intersection of research and clinical practice in this disease area. Because the award is intended to make research time realistically possible for busy clinicians, applications are strongly encouraged to document protected time of at least 40 percent devoted to prostate cancer research. That protected time does not have to be funded solely by this award and can include effort supported by other prostate cancer research activities, but reviewers want to see that the institution and mentoring structure genuinely make space for research productivity.

Mentorship is not optional in this mechanism. At least one mentor must be formally designated, and that mentor needs to have a demonstrably established prostate cancer research program, typically shown through recent peer-reviewed publications, active research funding, and a history of successful mentorship. Beyond credentials, the mentor must also show an active commitment to advancing the PI's long-term trajectory, not just supervising a single project. If the PI will rely on resources or expertise at another institution, the opportunity encourages naming a co-mentor at that collaborating site, which is a practical way to strengthen both the science and the training environment.

On the research side, proposals must address one or more of the FY22 PCRP Overarching Challenges, and the application needs to show that the PI understands the problem deeply and has a sound plan to tackle it. Reviewers expect a clear scientific rationale, well-described methods, and a realistic path to accomplishing the stated aims within the award period. Preliminary data are encouraged but not required, and if provided they should come from the PI, the mentor(s), or the collaborating team rather than unrelated sources. The announcement also emphasizes planning and documentation around access to key resources, meaning applicants are expected to identify what data, specimens, equipment, platforms, cohorts, or other infrastructure are needed and to back that up with appropriate letters or other support.

A required component is an individualized Researcher Development Plan built with mentor input. This plan is meant to be concrete rather than generic, laying out how the PI will gain the specific skills, competencies, and experiences needed to complete the project and grow into an independent prostate cancer investigator. The application must describe the overall training and research environment, and if the PI's home institution has gaps (for example, limited mentorship or specialized resources), those shortcomings can be addressed through structured collaborations with other institutions.

Impact is a major theme throughout the opportunity. The project is expected to contribute meaningfully to solving one or more Overarching Challenges and to align with the PCRP mission of eliminating death from prostate cancer and improving quality of life for those affected, with explicit relevance to military populations as well as the general public. To maximize translational value and credibility, applicants are encouraged to build in best practices such as cell line authentication, statistical rigor in animal studies, and experiments that connect findings to clinical relevance and eventual translatability. The program also encourages studies that leverage large patient datasets with long-term records and biospecimen repositories, especially when paired with modern genomics, proteomics, bioinformatics, or mathematical modeling approaches. Access letters for critical resources are strongly encouraged, signaling that feasibility and readiness matter.

Human subjects research is allowed, but clinical trials are explicitly not permitted. The opportunity does, however, encourage correlative studies linked to existing clinical trials when they are minimal risk, as determined by the responsible Institutional Review Board (IRB) and the US Army Medical Research and Development Command (USAMRDC) Office of Research Protections (ORP), Human Research Protection Office (HRPO). For projects involving human subjects, human anatomical substances, or cadavers, DoD requires additional HRPO review and approval before the work can begin, separate from local IRB approval, and applicants are advised to plan for the added review timeline. Multi-institution human subjects work requires a plan for a single IRB arrangement, including identification of the lead institution responsible for the master protocol and consent materials. For animal research, an additional DoD-level review is also required through ACURO (Animal Care and Use Review Office), again separate from local IACUC approval, and timelines of several months should be expected. The announcement also highlights standards for rigorous, reproducible study design and reporting, pointing applicants toward best practices like randomization, blinding, sample-size estimation, and ARRIVE 2.0 guidance for animal research.

From a funding and administrative standpoint, awards are issued as assistance agreements, meaning they will be made as either a grant or a cooperative agreement depending on how much substantial involvement the DoD anticipates during performance. Direct costs for the full period of performance are capped at $750,000. The program planned to allocate about $7.2 million total to fund roughly six awards, with actual funding dependent on federal availability and the outcome of scientific and programmatic review. Awards were expected to be made by September 30, 2023, and FY22 funds tied to awards were anticipated to remain available for use only through September 30, 2028. The opportunity also notes broader DoD priorities, including encouragement to consider recommendations from the congressionally mandated Metastatic Cancer Task Force, as long as the proposed work fits within this mechanism's rules and the FY22 PCRP priorities. Collaborations involving military or Veteran institutions are strongly encouraged to leverage unique populations, data resources, and infrastructure in ways that accelerate progress for the Warfighter community and beyond.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Prostate Cancer, Physician Research Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Apr 04, 2022.
• Applicants must submit their applications by Jul 28, 2022. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 6 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 22 PCRP PRA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: